Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients
The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.
Age ≥ 70 years; [+5]
Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemispher... [+19]